Lecithin-amended montmorillonite clays enhance the antibacterial effect of barrier creams.


Journal

Colloids and surfaces. B, Biointerfaces
ISSN: 1873-4367
Titre abrégé: Colloids Surf B Biointerfaces
Pays: Netherlands
ID NLM: 9315133

Informations de publication

Date de publication:
Sep 2023
Historique:
received: 21 04 2023
revised: 09 06 2023
accepted: 08 07 2023
medline: 11 8 2023
pubmed: 15 7 2023
entrez: 14 7 2023
Statut: ppublish

Résumé

The objective of this study was to assess in vitro antibacterial activity of barrier cream (EVB) formulations containing either calcium montmorillonite (CM) or lecithin-amended montmorillonite (CML). All ingredients were generally recognized as safe (GRAS), and clay minerals were specifically studied due to their known ability to adsorb numerous toxins of human clinical relevance. Characterization of the EVB formulations showed good spreadability, pH, appearance, unity, viscosity, and no evidence of phase separation. Colony forming, disk diffusion susceptibility, and agar dilution assays were used to determine the minimal bactericidal concentration (MBC) of total EVB formulations, as well as respective individual ingredients, against E. coli. Active ingredients within the base EVB formulation were found to be essential oils and zinc oxide. EVB-CML at 0.5-25 mg/mL dose-dependently and significantly (p ≤ 0.01) enhanced the antibacterial activity of the base EVB formulation. MBC values for EVB-CML were 2.5 mg/mL in the colony forming assay and 0.75 mg/mL in the agar dilution test, with a zone of inhibition. Both EVB and EVB-CML displayed stronger antibacterial activity than four antimicrobial creams currently marketed in the United States. Moreover, this effect was rapid, favored by high temperature, and product stability testing suggested a shelf life of at least 10 months. Taken together, these findings demonstrate the ability of CML to enhance the antibacterial effect of the base EVB formulation against E. coli. This novel EVB-CML formulation represents a promising advancement toward improved antibacterial efficacy beyond current industry standards for commercial skin creams and sunscreens.

Identifiants

pubmed: 37451226
pii: S0927-7765(23)00328-4
doi: 10.1016/j.colsurfb.2023.113450
pmc: PMC10528371
mid: NIHMS1917405
pii:
doi:

Substances chimiques

Lecithins 0
Bentonite 1302-78-9
Clay T1FAD4SS2M
Agar 9002-18-0
Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

113450

Subventions

Organisme : NIEHS NIH HHS
ID : K99 ES034090
Pays : United States
Organisme : NIEHS NIH HHS
ID : P42 ES027704
Pays : United States

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Colloids Surf B Biointerfaces. 2022 Jan;209(Pt 2):112186
pubmed: 34740094
Vet Microbiol. 2000 Jun 1;74(3):259-72
pubmed: 10808094
J Hazard Mater. 2013 Nov 15;262:439-46
pubmed: 24076479
Colloids Surf B Biointerfaces. 2020 Mar;187:110652
pubmed: 31785852
Acta Derm Venereol. 2010 May;90(3):239-45
pubmed: 20526539
ACS Appl Mater Interfaces. 2022 May 10;:
pubmed: 35536196
ACS Appl Bio Mater. 2021 Sep 20;4(9):7254-7265
pubmed: 34746680
Colloids Surf B Biointerfaces. 2019 Nov 1;183:110416
pubmed: 31398622
J Environ Sci (China). 2024 Jan;135:669-680
pubmed: 37778837
Water Res. 2008 Apr;42(8-9):2260-8
pubmed: 18221769
Appl Spectrosc. 2010 Sep;64(9):1017-21
pubmed: 20828438
Mater Sci Eng C Mater Biol Appl. 2017 Oct 1;79:581-589
pubmed: 28629056
J Clin Microbiol. 2009 Jun;47(6):1811-7
pubmed: 19357208
J Agric Food Chem. 1998 Feb 16;46(2):599-605
pubmed: 10554284
J Bacteriol. 2007 Dec;189(23):8746-9
pubmed: 17905994
Molecules. 2019 Jun 05;24(11):
pubmed: 31195752
Colloids Surf B Biointerfaces. 2021 Jan;197:111424
pubmed: 33099148
Iran J Public Health. 2017 Sep;46(9):1176-1183
pubmed: 29026782
Sci Technol Adv Mater. 2019 Dec 2;20(1):1150-1163
pubmed: 32082437
Sci Rep. 2020 Jan 17;10(1):577
pubmed: 31953500
Can J Infect Dis Med Microbiol. 2008 Mar;19(2):173-84
pubmed: 19352449
J Hazard Mater. 2021 Apr 15;408:124425
pubmed: 33162237
Colloids Surf B Biointerfaces. 2015 Apr 1;128:473-479
pubmed: 25797482
Medicines (Basel). 2017 Aug 08;4(3):
pubmed: 28930272

Auteurs

Meichen Wang (M)

Interdisciplinary Faculty of Toxicology, College Station, TX 77843, USA; Department of Veterinary Physiology and Pharmacology, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX 77843, USA.

Timothy D Phillips (TD)

Interdisciplinary Faculty of Toxicology, College Station, TX 77843, USA; Department of Veterinary Physiology and Pharmacology, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX 77843, USA. Electronic address: tphillips@cvm.tamu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH